Quest Diagnostics (DGX) – Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Quest Diagnostics (NYSE: DGX) in the last few weeks:

• 7/29/2026 – Quest Diagnostics was given a new $260.00 price target by Argus.
• 7/28/2026 – Quest Diagnostics had its price target raised by JPMorgan Chase & Co. from $220.00 to $250.00. They now have a “neutral” rating on the stock.
• 7/28/2026 – Quest Diagnostics was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/24/2026 – Quest Diagnostics had its price target raised by UBS Group AG from $220.00 to $232.00. They now have a “neutral” rating on the stock.
• 7/24/2026 – Quest Diagnostics had its price target raised by Mizuho from $235.00 to $260.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – Quest Diagnostics had its price target raised by Truist Financial Corporation from $225.00 to $250.00. They now have a “hold” rating on the stock.
• 7/24/2026 – Quest Diagnostics had its price target raised by Robert W. Baird from $236.00 to $255.00. They now have a “neutral” rating on the stock.
• 7/23/2026 – Quest Diagnostics had its price target raised by Barclays PLC from $230.00 to $250.00. They now have an “overweight” rating on the stock.
• 7/23/2026 – Quest Diagnostics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $245.00 price target on the stock.
• 7/20/2026 – Quest Diagnostics was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/13/2026 – Quest Diagnostics had its price target raised by Robert W. Baird from $232.00 to $236.00. They now have a “neutral” rating on the stock.
• 7/12/2026 – Quest Diagnostics was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/9/2026 – Quest Diagnostics was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 6/28/2026 – Quest Diagnostics was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/24/2026 – Quest Diagnostics was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 6/20/2026 – Quest Diagnostics was upgraded by Wall Street Zen from “hold” to “buy”.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. Quest Diagnostics’s dividend payout ratio (DPR) is 36.52%.

Insider Buying and Selling

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the sale, the senior vice president directly owned 13,510 shares in the company, valued at approximately $2,702,000. The trade was a 37.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the transaction, the senior vice president owned 10,335 shares in the company, valued at $2,430,585.30. This represents a 13.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 19,747 shares of company stock worth $3,947,088 in the last 90 days. Insiders own 0.88% of the company’s stock.

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.